Eisai acquires rights to Bial epilsepsy candidate
The European subsidiary of Japan's Eisai has acquired the European marketing rights to the novel once-daily anti-epileptic Zebinix (eslicarbazepine) from Portugal's largest pharmaceutical firm, Bial-Portela & CA.
Under the terms of the agreement, Bial will receive 95.0 million euros ($121.6 million), consisting of an upfront payment and milestones for further European epilepsy approvals. The Portuguese firm will maintain ongoing development and production rights and the option to co-promote the drug throughout Europe, and will supply finished product to Eisai.
Zebinix is intended for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients with epilepsy. The drug was submitted to the European Medicines Agency (EMEA) in March 2008 and approval is anticipated in the second quarter of 2009.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze